首页> 外文OA文献 >A New Surgical Technique of Pancreaticoduodenectomy with Splenic Artery Resection for Ductal Adenocarcinoma of the Pancreatic Head and/or Body Invading Splenic Artery: Impact of the Balance between Surgical Radicality and QOL to Avoid Total Pancreatectomy
【2h】

A New Surgical Technique of Pancreaticoduodenectomy with Splenic Artery Resection for Ductal Adenocarcinoma of the Pancreatic Head and/or Body Invading Splenic Artery: Impact of the Balance between Surgical Radicality and QOL to Avoid Total Pancreatectomy

机译:一种新的胰腺癌切除术治疗胰腺头腺癌和/或身体入侵脾动脉的脾动脉切除:外科自然度和QOL之间平衡的影响,避免总胰腺切除术

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

For pancreatic ductal adenocarcinoma (PDAC) of the head and/or body invading the splenic artery (SA), we developed a new surgical technique of proximal subtotal pancreatectomy with splenic artery and vein resection, so-called pancreaticoduodenectomy with splenic artery resection (PD-SAR). We retrospectively reviewed a total of 84 patients with curative intent pancreaticoduodenectomy (PD) for PDAC of the head and/or body. These 84 patients were classified into the two groups: conventional PD (n=66) and PD-SAR (n=18). Most patients were treated by preoperative chemoradiotherapy (CRT). Postoperative MDCT clearly demonstrated enhancement of the remnant pancreas at 1 and 6 months in all patients examined. Overall survival rates were very similar between PD and PD-SAR (3-year OS: 23.7% versus 23.1%, P=0.538), despite the fact that the tumor size and the percentages of UICC-T4 determined before treatment were higher in PD-SAR. Total daily insulin dose was significantly higher in PD-SAR than in PD at 1 month, while showing no significant differences between the two groups thereafter. PD-SAR with preoperative CRT seems to be promising surgical strategy for PDAC of head and/or body with invasion of the splenic artery, in regard to the balance between operative radicality and postoperative QOL.
机译:对于头部和/或身体侵犯脾动脉(SA)的胰腺导管腺癌(PDAC),我们开发的近端小计胰腺切除与脾动脉和静脉切除了新的手术技术,所谓的胰十二指肠切除术与脾动脉切除术(PD- SAR)。我们回顾一共有84例治愈性胰十二指肠切除术(PD)的头部和/或身体的PDAC。这些84名患者被分类成两组:常规PD(N = 66)和PD-SAR(N = 18)。大多数患者术前放化疗(CRT)处理。术后MDCT清楚地表明增强残留胰腺的1年和6个月的所有患者检查。总生存率分别为PD和PD-SAR之间非常相似(3年OS:23.7%比23.1%,P = 0.538),尽管肿瘤的大小和UICC-T4的百分比治疗前确定的事实PD较高-Sar。每日总胰岛素剂量是PD-SAR显著高于PD在1个月,而其后显示两组间无显著差异。 PD-SAR术前CRT似乎是有前途的手术策略,头部和/或身体的PDAC与脾动脉的入侵,在关于执行的激进和术后生活质量之间的平衡。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号